These results claim that targeting Nrf2 signaling may be a novel therapeutic technique for the treating maladaptive cardiac hypertrophy and preventing heart failure. dh404 didn’t dissociate the relationship of Nrf2 using the Keap1-Cul3-Rbx1 E3 ligase complicated. Thus, chances are that dh404 inhibits the power of Keap1-Cul3-Rbx1 E3 ligase complicated to focus on Nrf2 for ubiquitination and degradation via changing Cys-151 of Keap1 to change the conformation of the complex. Moreover, dh404 was able to stabilize Nrf2 protein, to enhance Nrf2 nuclear translocation, to activate Nrf2-driven transcription, and to suppress angiotensin HAE II (Ang II)-induced oxidative stress in cardiomyocytes. Knockdown of Nrf2 almost blocked the anti-oxidative effect of dh404. Dh404 activated Nrf2 signaling in the heart. Taken together, dh404 appears to be a novel Nrf2 activator HAE with a therapeutic potential for cardiac diseases via suppressing oxidative stress. == Introduction == Triterpenoids, synthesized in TRADD many plants, including a large variety of vegetarian foods and medicinal herbs, are widely used as traditional medicine of in Asian countries[1]. More than 20,000 triterpenoids exist in nature[2]. In fact, triterpenoids of oleanolic acid (OA) and ursolic acid (UA) have emerged to be attractive drug scaffolds because they are relatively non-toxic, cytoprotective, hypoglycemic, anti-inflammatory, anti-hyperlipidemic, and anti-tumorigenic[1]. To improve the pharmacological potency, novel derivatives of OA, such as 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO), CDDO methyl ester (CDDO-Me), CDDO imidazolides (CDDO-Im), and CDDO amides (methyl amide, CDDO-MA; ethyl amide, CDDO-EA), have been synthesized[3]. These synthetic derivatives of OA are potent multifunctional moleculesin vitro. Depending on the dose, they can suppress inflammation, HAE activate cytoprotective pathways, induce differentiation, inhibit proliferation and induce apoptosis. In fact, they are the most potent anti-inflammatory and anti-carcinogenic triterpenoinds identified[4]. Importantly, CDDO-Me that has been tested in clinical oncology trails is currently in a phase IIb clinical trial for the treatment of chronic kidney diseases. However, the therapeutic potential of synthetic oleanane triterpenoids (SO) in cardiovascular diseases has not been explored. Molecular mechanisms underlying the pleiotropic nature of SO are only partly comprehended. However; it has been recently exhibited that activation of nuclear factor-erythroid (NF-E) 2related factor 2 (Nrf2) signaling is critical for the SO-mediated anti-inflammatory and anti-carcinogenic activities[4]. Nrf2 is usually a member of the Cap n Collar (CNC) family of basic leucine zipper (bZip) transcription factors that includes NF-E2, Nrf1-3 and Bach1-2[5][9]. As other members of the CNC family of bZip transcription factors, Nrf2 forms a heterodimer with its obligatory partner Maf, thereby binding to acis-acting enhancer sequence known as the antioxidant response element (ARE), also referred to as the electrophile response element (EpRE) with a core nucleotide sequence of 5-RTGACNNNGC-3, to regulate the basal and inducible expression of more than 200 genes that can be grouped into several categories including antioxidant genes, phase II detoxifying enzymes, transporters, scavenger receptor, chaperone proteins, transcription factors[10][12]. The protein stability and transcriptional activity of Nrf2 is principally regulated by a BTB-Kelch protein, Keap1 that functions as a substrate adaptor for a cullin (Cul)3-dependent E3 ubiquitin ligase complex[10][12]. Keap1 targets Nrf2 for ubiquitination and subsequent degradation by the 26S proteasome. Mounting evidence has revealed that Nrf2 is usually a major regulator of cellular defenses against various pathological stresses in different organs including lung, liver, gastrointestinal tract, bladder, kidney, brain, skin, and ovary. Nrf2 also appears to be an attractive drug target for the treatment or prevention of several human disorders such as pulmonary fibrosis, hepatic and gastrointestinal disease, carcinogenesis and neurodegenerative disease[12][23]. Of note, we have recently exhibited that Nrf2 is usually a critical unfavorable regulator of pathological cardiac hypertrophy and heart failure via its ability to orchestrate a group of antioxidant genes[24]. These results suggest that targeting Nrf2 signaling might be a novel therapeutic strategy for the treatment of maladaptive cardiac hypertrophy and the prevention of heart failure. Interestingly, a recent report highlighted the fact that this Keap1-Nrf2 system comprises discrete sensor sites, including the Keap1 cysteines Cys-151 and Cys-275, for a variety of Nrf2-activating compounds and special cysteine codes are.
These results claim that targeting Nrf2 signaling may be a novel therapeutic technique for the treating maladaptive cardiac hypertrophy and preventing heart failure
